The Timing Hypothesis: Hormone Therapy for Treating Symptomatic Women During Menopause and Its Relationship to Cardiovascular Disease - PubMed (original) (raw)
. 2019 May;28(5):705-711.
doi: 10.1089/jwh.2018.7201. Epub 2018 Nov 28.
Affiliations
- PMID: 30484736
- DOI: 10.1089/jwh.2018.7201
The Timing Hypothesis: Hormone Therapy for Treating Symptomatic Women During Menopause and Its Relationship to Cardiovascular Disease
Jaya M Mehta et al. J Womens Health (Larchmt). 2019 May.
Abstract
The risks and benefits of menopausal hormonal therapy (HT) have been evaluated extensively over the past three decades. While the efficacy of HT for management of menopausal symptoms, including vasomotor symptoms and vaginal dryness is well established, its relationship to cardiovascular outcomes is complex. The timing hypothesis, which posits that the cardiovascular effects of HT depend on the timing of initiation of HT in relation to menopause, has helped shape our understanding of the cardiovascular outcomes related to HT. Based on results from female monkey studies, the timing hypothesis provides a framework to explain discrepancies in results between multiple observation studies and the Women's Health Initiative (WHI) hormone therapy trials. The WHI trials closed early in 2002 in part because of increased cardiovascular events seen in women on treatment. Subanalysis of the WHI results by age group, and more recent randomized control studies, including the Kronos Early Estrogen and Prevention Study (KEEPS) and Early Versus Late Intervention Trial (ELITE), demonstrate that the risk of adverse cardiovascular events for HT are low for women <60 years of age or within 10 year from menopause. Although current data does not support using HT for primary prevention of cardiovascular disease, it does suggest that HT can be safely used to treat symptoms in appropriately selected women close to menopause.
Keywords: cardiovascular health; hormone therapy; postmenopausal hormone therapy.
Similar articles
- Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts.
Mehta J, Kling JM, Manson JE. Mehta J, et al. Front Endocrinol (Lausanne). 2021 Mar 26;12:564781. doi: 10.3389/fendo.2021.564781. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33841322 Free PMC article. Review. - The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
Parish SJ, Gillespie JA. Parish SJ, et al. Postgrad Med. 2017 Apr;129(3):340-351. doi: 10.1080/00325481.2017.1281083. Epub 2017 Jan 30. Postgrad Med. 2017. PMID: 28132583 Review. - AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.
Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. Cobin RH, et al. Endocr Pract. 2017 Jul;23(7):869-880. doi: 10.4158/EP171828.PS. Endocr Pract. 2017. PMID: 28703650 - Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
Harman SM, Naftolin F, Brinton EA, Judelson DR. Harman SM, et al. Ann N Y Acad Sci. 2005 Jun;1052:43-56. doi: 10.1196/annals.1347.004. Ann N Y Acad Sci. 2005. PMID: 16024750 - Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis.
Hodis HN, Mack WJ, Shoupe D, Azen SP, Stanczyk FZ, Hwang-Levine J, Budoff MJ, Henderson VW. Hodis HN, et al. Menopause. 2015 Apr;22(4):391-401. doi: 10.1097/GME.0000000000000343. Menopause. 2015. PMID: 25380275 Free PMC article. Clinical Trial.
Cited by
- Association between Menopausal Hormone Therapy and Frailty: Cross-Sectional Study Using National Survey Data in Korea.
Kim H, Lee E. Kim H, et al. Healthcare (Basel). 2022 Oct 24;10(11):2121. doi: 10.3390/healthcare10112121. Healthcare (Basel). 2022. PMID: 36360462 Free PMC article. - Gestational Weight Gain and Long-term Maternal Obesity Risk: A Multiple-Bias Analysis.
Hutchins F, Krafty R, El Khoudary SR, Catov J, Colvin A, Barinas-Mitchell E, Brooks MM. Hutchins F, et al. Epidemiology. 2021 Mar 1;32(2):248-258. doi: 10.1097/EDE.0000000000001310. Epidemiology. 2021. PMID: 33284167 Free PMC article. - Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts.
Mehta J, Kling JM, Manson JE. Mehta J, et al. Front Endocrinol (Lausanne). 2021 Mar 26;12:564781. doi: 10.3389/fendo.2021.564781. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33841322 Free PMC article. Review. - The Effect of Ovariectomy and Estradiol Substitution on the Metabolic Parameters and Transcriptomic Profile of Adipose Tissue in a Prediabetic Model.
Marková I, Hüttl M, Miklánková D, Šedová L, Šeda O, Malínská H. Marková I, et al. Antioxidants (Basel). 2024 May 21;13(6):627. doi: 10.3390/antiox13060627. Antioxidants (Basel). 2024. PMID: 38929066 Free PMC article. - Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis.
Harder H, Starkings RML, Fallowfield LJ, Menon U, Jacobs IJ, Jenkins VA; UKCTOCS trialists. Harder H, et al. Menopause. 2019 Oct;26(10):1100-1109. doi: 10.1097/GME.0000000000001377. Menopause. 2019. PMID: 31290761 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous